Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy

Conclusion
The evidence in this study implies that baseline IL-6 could be a biomarker of DP and poor prognosis in BRAFwt MM patients treated with pembrolizumab.

Source: Journal of Clinical Pathology - April 18, 2024 Category: Pathology Authors: Mirjacic Martinovic, K., Vuletic, A., Tisma Miletic, N., Matkovic, S., Gavrilovic, D., Ninkovic, A., Jurisic, V., Babovic, N. Tags: Original research Source Type: research